Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2009

View Archived Issues

New data demonstrate potential of GLP-1 analogues for neurodegenerative diseases

Baminercept is safe but has no apparent efficacy in phase Ib trials in RA

LX-2931 is safe in combination with methotrexate in patients with stable RA

Antisense oligonucleotides targeting huntingtin show promise for the treatment of HD

Amura describes cathepsin S inhibitors for the treatment of RA

Tubulin polymerization inhibitors for cancer therapy presented by U.S. scientists

Novel MEK inhibitor G-573 tested in tumor xenograft models

AMT and Progenika to develop LPLchip to diagnose lipoprotein lipase deficiency

BioPorto reports technical data of NGAL diagnostic test for acute kidney injury

BioMerieux launches MRSA screening tool

Thermo Fisher Scientific launches new biomarker test for heart attack

Morphotek enters into licensing agreement with Centocor for anticancer therapeutic antibody

Sunesis completes enrollment in voreloxin trial in acute myeloid leukemia

AcelRx completes end-of-phase II meeting for ARX-01 analgesic

UCB reports results from third quarter of 2009

Shire reports tolerability and clinical effects of Daytrana in adolescents with ADHD

HGS and GSK report results for second of two phase III Benlysta trials in SLE

Lundbeck starts clinical phase IIa trial of Lu-AA24493 in Friedreich's ataxia

Byetta approved for expanded use as first-line treatment for type 2 diabetes

FDA issues complete response letter regarding Schering-Plough's sBLA for Pegintron

Solasia completes phase I trial of Sancuso for chemotherapy-induced nausea

Geron and FDA agree on conditions to lift clinical hold on phase I trial of GRNOPC1

ATLAS I and II data show efficacy of telavancin in cellulitis and infected ulcers

Novel hybrid peptide vaccine is safe and immunogenic in phase I trial in prostate cancer

M1 receptor agonists for the treatment of pain claimed by AstraZeneca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...